Ceftriaxone
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Antibiotics | Ceftriaxone | 1-2g IV Q12-24H | Administer Anytime During HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 555 | 30-65 | 7-9 | 12-24 | 90 | 0.12-0.18 | 6-41.9 | 21-24 (high flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- Cohen D, Appel G, Scully B, Neu H. Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis. Antimicrobial agents and chemotherapy 1983; 24(4), 529-32.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB01212
- Gabutti L, Taminelli-Beltraminelli L, Marone C. Clearance of ceftriaxone during haemodialysis using cuprophane, haemophane and polysulfone dialysers. European journal of clinical pharmacology 1997; 53(2), 123-6.
- Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
- Matzke G. Status of Hemodialysis of Drugs in 2002. Journal of Pharmacy Practice 2002; 15(5), 405-418.
- Matzke G, Frye R, Joy M, Palevsky P. Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis. Pharmacotherapy 2000; 20(6), 635-43.
- Patel I, Sugihara J, Weinfeld R, Wong E, Siemsen A, Berman S. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrobial agents and chemotherapy 1984; 25(4), 438-42.
- Simon N, Dussol B, Sampol E et al. Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients. Clinical pharmacokinetics 2006; 45(5), 493-501.
- Ti T, Fortin L, Kreeft J, East D, Ogilvie R, Somerville P. Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis. Antimicrobial agents and chemotherapy 1984; 25(1), 83-7.